Tags : Instituto Butantan

Merck Collaborates with Instituto Butantan to Develop Vaccines for Dengue

Shots: Instituto Butantan to receive $26M upfront, $75M milestones and royalties on sales from Merck. Merck to get clinical data and learnings (utilized for its TV003, dengue vaccine) from Instituto’s development programs to develop vaccines for dengue The focus of the agreement is to develop live attenuated tetravalent vaccines (LATV) against the dengue virus for patients suffering in Brazil TV003 is […]Read More